Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus RemediesBOM:526953 -1.21%51 EV-to-EBIT is 14.32 as of Sep. 05, 2026, which is 65% above its 10-year median of 8.68. GuruFocus rates BOM:526953 with a GF Score™ of 51/100 and a GF Value™ of ₹526.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 682 Drug Manufacturers companies, Venus Remedies ranks better than 54.25% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Venus Remedies's Enterprise Value for the quarter that ended in Jun. 2026 was ₹24,972 Mil.
Venus Remedies's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,516 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies EV-to-EBIT Related Terms
Venus Remedies EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Venus Remedies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Venus Remedies's EV-to-EBIT falls into.
Venus Remedies's current Enterprise Value is ₹21,715 Mil.
Venus Remedies's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,516 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies (BOM:526953) has a EV-to-EBIT of 14.32 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Venus Remedies and its competitors. This is 65% above median its historical median of 8.68. According to the industry distribution chart, Venus Remedies ranks #312 out of 682 companies in the Drug Manufacturers industry, placing it in the top 45.7%.
Is Venus Remedies' EV-to-EBIT too high?
Venus Remedies' current EV-to-EBIT of 14.32 is 65% above median its 10-year median of 8.68. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Venus Remedies' value of 14.32 is 10.4% below this industry median. Based on the distribution chart, Venus Remedies ranks #312 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Venus Remedies has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #312 out of 682 companies for EV-to-EBIT. This puts Venus Remedies in the upper half of its industry. The industry median EV-to-EBIT is 15.99. Venus Remedies' value of 14.32 is 10.4% below this benchmark. While the company's 10-year median is 8.68 vs. the industry median of 15.99, Venus Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current EV-to-EBIT of 14.32 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current EV-to-EBIT is 14.32, which is 65% above median its own 10-year median of 8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹526.54, compared to a current price of ₹1,689.25 — trading 220.8% above its estimated fair value. The current EV-to-EBIT is 14.32, which is 65% above median its 10-year median of 8.68 and 10.4% below the Drug Manufacturers industry median of 15.99. Venus Remedies' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current EV-to-EBIT is 14.32 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (BOM:526953) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,689.25 is trading 220.8% above its estimated GF Value™ of ₹526.54.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for BOM:526953:
EV-to-EBIT: 14.32 (65% above median its 10-year median of 8.68)
GF Value™: ₹526.54 vs. price of ₹1,689.25 (220.8% above fair value)
Industry Position: 10.4% below the Drug Manufacturers median (#312 of 682)
No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
51GF Score
Get the complete analysis for BOM:526953
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526953 has been successfully added to your 
